Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/nrc.2016.154 http://scihub22266oqcxt.onion/10.1038/nrc.2016.154 C5575801!5575801!28233802     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Rev+Cancer 2017 ; 17 (4): 209-22 Nephropedia Template TP {{tp|p=28233802|t=2017. Targeting neoantigens to augment antitumour immunity |pdf=|usr=}}{{28233802}} gab.com Text Targeting neoantigens to augment antitumour immunity JO: Nat Rev Cancer http://www.kidney.de/pget.php?&tw=1&pmid=28233802 #FOAvip The past decade of cancer research has been marked by a growing appreciation of the role of immunity in cancer. Mutations in the tumour genome can cause tumours to express mutant proteins that are tumour specific and not expressed on normal cells (neoantigens). These neoantigens are an attractive immune target because their selective expression on tumours may minimize immune tolerance as well as the risk of autoimmunity. In this Review we discuss the emerging evidence that neoantigens are recognized by the immune system and can be targeted to increase antitumour immunity. We also provide a framework for personalized cancer immunotherapy through the identification and selective targeting of individual tumour neoantigens, and present the potential benefits and obstacles to this approach of targeted immunotherapy. Twit Text FOAVip Targeting neoantigens to augment antitumour immunity ????Nat Rev Cancer http://www.kidney.de/pget.php?&tw=1&pmid=28233802 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28233802 #FOAvip English Wikipedia <ref>{{Cite pmid|28233802}}</ref> Targeting neoantigens to augment antitumour immunity #MMPMID28233802 Yarchoan M; Johnson BA; Lutz ER; Laheru DA; Jaffee EM Nat Rev Cancer 2017[Apr]; 17 (4): 209-22 PMID28233802show ga The past decade of cancer research has been marked by a growing appreciation of the role of immunity in cancer. Mutations in the tumour genome can cause tumours to express mutant proteins that are tumour specific and not expressed on normal cells (neoantigens). These neoantigens are an attractive immune target because their selective expression on tumours may minimize immune tolerance as well as the risk of autoimmunity. In this Review we discuss the emerging evidence that neoantigens are recognized by the immune system and can be targeted to increase antitumour immunity. We also provide a framework for personalized cancer immunotherapy through the identification and selective targeting of individual tumour neoantigens, and present the potential benefits and obstacles to this approach of targeted immunotherapy. äTargeting neoantigens to augment antitumour immunity (epmc).pdf DeepDyve Pubget Overpricing